Andes virus (ANDV) is a highly pathogenic hantavirus native to South America that causes Hantavirus Pulmonary Syndrome (HPS). It is unique among hantaviruses for its documented ability to spread via person-to-person transmission. Cases primarily occur in Argentina and Chile, often linked to contact with the long-tailed pygmy rice rat.
Introduction to Andes Virus (ANDV)
The Andes virus (ANDV) represents one of the most significant public health challenges in the southern cone of South America. As a member of the Orthohantavirus genus, it is the primary etiologic agent of Hantavirus Pulmonary Syndrome (HPS) in Argentina and Chile. While many hantaviruses exist globally—ranging from the Seoul virus in Asia to the Sin Nombre virus in North America—Andes virus stands apart due to its specific evolutionary adaptations and its devastating clinical impact.
First identified in 1995 following an outbreak in El Bolsón, Argentina, the virus was named after the mountain range that defines the geography of the region. It is a single-stranded, negative-sense RNA virus. Its genome is divided into three segments: Small (S), Medium (M), and Large (L), which encode the nucleocapsid protein, the envelope glycoproteins (Gn and Gp), and the viral RNA polymerase, respectively. Understanding these molecular components is crucial for clinicians and researchers as they attempt to develop vaccines and targeted therapies, which as of 2026, remain areas of intense active study.
The primary reservoir for the virus is the long-tailed pygmy rice rat (Oligoryzomys longicaudatus). This small rodent thrives in the temperate forests and shrublands of the Andean foothills. Human cases are traditionally associated with rural or peri-urban areas where human activity overlaps with the natural habitat of these rodents. However, the unique biological characteristics of ANDV mean that cases can also arise in clusters far removed from the original zoonotic source.
Transmission Dynamics: Why Andes Virus is Unique
The transmission of Andes virus follows two distinct pathways: zoonotic spillover and inter-human spread. The latter is what makes Andes virus cases a matter of global concern for epidemiologists.
Zoonotic Transmission (Animal-to-Human)
The most common way humans contract the Andes virus is through the inhalation of aerosolized viral particles. These particles are shed in the saliva, urine, and feces of infected Oligoryzomys longicaudatus rodents. When a person disturbs dried nesting material or sweeps out a shed where rodents have been active, the virus becomes airborne.
Direct contact with infected rodents or their excreta, as well as bites, are less common but documented routes of infection. In 2026, public health guidelines emphasize that even brief exposure in confined, poorly ventilated spaces—such as cabins or storage units—can be sufficient for transmission if the viral load in the environment is high.
Person-to-Person Transmission
Andes virus is currently the only hantavirus with definitive evidence of person-to-person transmission. This was first suspected during the 1995 outbreak and was rigorously confirmed through genetic sequencing during subsequent clusters. Transmission usually occurs during the prodromal phase (the early stage of symptoms) or the early stages of respiratory distress.
Research indicates that close, prolonged contact is typically required for inter-human spread. This often occurs within households or among healthcare workers who are not utilizing appropriate personal protective equipment (PPE). The virus is believed to be present in respiratory secretions, though the exact mechanism—whether through droplets or fine aerosols—continues to be a subject of academic refinement. This capability necessitates strict isolation protocols for suspected Andes virus cases that are not required for other hantaviruses.
Analyzing Historical Andes Virus Cases and Outbreaks
The history of Andes virus is marked by sporadic cases and occasional large-scale outbreaks that have reshaped our understanding of viral epidemiology.
The 1995 El Bolsón Outbreak
This was the foundational event for Andes virus research. Located in the Rio Negro Province of Argentina, the outbreak initially appeared to be a standard zoonotic event. However, investigators noticed that several patients had no history of exposure to rodents but had close contact with previous victims. This led to the groundbreaking discovery that ANDV could jump between humans, a finding that initially met with skepticism in the scientific community but was eventually proven through molecular epidemiology.
The 2018-2019 Epuyén Outbreak
The outbreak in Epuyén, Chubut Province, Argentina, remains the most significant documented cluster of person-to-person transmission. It began at a social gathering and eventually resulted in 34 confirmed cases and 11 deaths. What made this outbreak particularly alarming was the high secondary attack rate.
Public health authorities had to implement unprecedented mandatory isolation measures for over 100 people to break the chain of transmission. This event highlighted the potential for ANDV to cause localized epidemics that mimic the behavior of more traditional "contagious" viruses, rather than just isolated environmental accidents.
Patterns in Chile
In Chile, Andes virus cases are reported annually, with a notable seasonality. Most cases occur during the spring and summer months (October to March) when human recreational activity in rural areas increases and the rodent population reaches its peak. The Chilean Ministry of Health (MINSAL) maintains a rigorous surveillance system, noting that while the number of cases may fluctuate based on ecological factors like the "florecimiento de la quila" (the flowering of native bamboo which provides a massive food source for rodents), the case fatality rate remains stubbornly high, often exceeding 30%.
Clinical Presentation and Symptoms of HPS
Andes virus leads to Hantavirus Pulmonary Syndrome (HPS), a severe and often fatal respiratory disease. The clinical course is typically divided into three distinct phases.
1. The Incubation Period
The incubation period for Andes virus is notably long, typically ranging from 7 to 39 days, with an average of about 18 days. This long window makes contact tracing difficult, as patients may not immediately associate their symptoms with an event that occurred weeks prior.
2. The Prodromal Phase
The illness begins with non-specific, flu-like symptoms. Patients frequently report:
- High fever and chills.
- Myalgia (severe muscle aches, particularly in the thighs, back, and shoulders).
- Headache and dizziness.
- Gastrointestinal distress, including abdominal pain, vomiting, and diarrhea.
Because these symptoms overlap with many other regional diseases—such as influenza, COVID-19, or dengue fever—early diagnosis is extremely challenging. A key clinical "red flag" for Andes virus is the absence of upper respiratory symptoms (like a runny nose or sore throat) during this initial febrile stage.
3. The Cardiopulmonary Phase
Usually 3 to 7 days after the onset of fever, the patient’s condition can deteriorate rapidly. This phase is characterized by the sudden onset of progressive pulmonary edema and shock. The virus causes increased vascular permeability, leading the lungs to fill with fluid.
Symptoms include:
- Severe shortness of breath (dyspnea).
- Tachycardia (rapid heart rate).
- Hypotension (low blood pressure).
- Cardiovascular collapse.
In 2026, this phase is still considered a medical emergency requiring intensive care. Once the cardiopulmonary phase begins, the disease progresses with frightening speed; patients may transition from mild distress to requiring mechanical ventilation within hours.
Diagnosis and Laboratory Testing
Early diagnosis is the most critical factor in improving survival rates for Andes virus cases. Because the clinical presentation is so similar to other illnesses, laboratory confirmation is essential.
- Seriology (ELISA): The most common diagnostic tool is the detection of specific IgM antibodies or a four-fold increase in IgG titers. IgM antibodies are usually detectable at the onset of clinical symptoms.
- Molecular Testing (RT-PCR): Reverse Transcription Polymerase Chain Reaction is used to detect viral RNA in blood or tissue samples. This is particularly useful in the very early stages of the disease before an antibody response has fully mounted.
- Immunohistochemistry: In fatal cases, the diagnosis can be confirmed by detecting hantavirus antigens in lung or heart tissue.
Clinicians also look for specific hematological markers that suggest HPS, including thrombocytopenia (low platelet count), hemoconcentration (increased hematocrit), and the presence of atypical lymphocytes. The "Hantavirus Triad"—thrombocytopenia, left-shift leukocytosis, and immunoblasts—is a strong indicator used by ICU teams to initiate presumptive treatment.
Treatment Protocols and Patient Management
As of 2026, there is no FDA-approved or WHO-cleared specific antiviral therapy that has been proven to cure Andes virus. Treatment remains primarily supportive, focusing on maintaining oxygenation and managing hemodynamic stability.
Supportive Care
The cornerstone of treatment is admission to an Intensive Care Unit (ICU). Management includes:
- Mechanical Ventilation: Most patients require respiratory support. However, clinicians must be careful to avoid barotrauma, as the lungs in HPS patients are extremely fragile.
- Fluid Management: Balancing fluids is precarious. While patients are often in shock, over-aggressive fluid resuscitation can worsen pulmonary edema.
- Vasoactive Drugs: Medications to support blood pressure are frequently necessary.
Extracorporeal Membrane Oxygenation (ECMO)
ECMO has emerged as a life-saving intervention for the most severe Andes virus cases. By bypassing the lungs and heart, ECMO allows the patient's organs to rest while the immune system fights the virus. In specialized centers in Santiago and Buenos Aires, the use of ECMO has been credited with significantly reducing the mortality rate of HPS.
Experimental Therapies
Research into neutralizing antibodies and convalescent plasma (using blood from HPS survivors) continues. While some small-scale studies showed promise, large-scale clinical trials are difficult to conduct due to the sporadic nature of the cases. Antiviral drugs like Ribavirin have been tested but have not shown significant efficacy in the pulmonary phase of the disease.
Comparative Overview: Andes Virus vs. Other Hantaviruses
To understand the specific risks associated with Andes virus cases, it is helpful to compare them to other well-known hantaviruses.
| Feature | Andes Virus (ANDV) | Sin Nombre Virus (SNV) | Puumala Virus (PUUV) |
|---|---|---|---|
| Primary Region | Argentina, Chile | North America (USA, Canada) | Europe, Scandinavia |
| Primary Reservoir | Oligoryzomys longicaudatus | Peromyscus maniculatus | Myodes glareolus |
| Primary Disease | Hantavirus Pulmonary Syndrome | Hantavirus Pulmonary Syndrome | Nephropathia Epidemica (HFRS) |
| Person-to-Person | Confirmed | Not Documented | Not Documented |
| Fatality Rate | 30% – 40% | 35% – 50% | < 1% |
| Incubation Period | 7 – 39 Days | 9 – 33 Days | 2 – 6 Weeks |
Prevention and Risk Mitigation in 2026
Prevention remains the most effective tool against Andes virus. Because a vaccine is not yet widely available for public use in 2026, efforts focus on environmental control and behavioral modification.
- Rodent-Proofing: Residents in endemic areas are advised to seal all holes and cracks in homes and outbuildings.
- Safe Cleaning Practices: Never sweep or vacuum rodent-infested areas. Instead, spray the area with a 10% bleach solution and let it soak for 30 minutes before cleaning with paper towels while wearing gloves and an N95 mask.
- Camping Safety: Travelers should avoid sleeping on the ground in areas where the long-tailed pygmy rice rat is active. Using tents with floors and keeping food in airtight containers is essential.
- Awareness of "Masting" Events: Local health departments monitor the flowering of bamboo and other vegetation. When a "masting" event occurs, the sudden abundance of food leads to a "rodent irruption," significantly increasing the risk of spillover cases.
FAQ
Can I get Andes virus from a mosquito or tick?
No. Andes virus is a zoonotic disease spread primarily by rodents. There is no evidence that mosquitoes, ticks, or other arthropods can transmit the virus to humans. Transmission is limited to rodent excreta or close contact with an infected human.
Is there a vaccine for Andes virus?
As of 2026, several vaccine candidates are in various stages of clinical trials, including DNA-based and viral-vector vaccines. However, none have been deployed for general public use. Prevention currently relies on avoiding exposure to rodents and their habitats.
How do I know if I have Hantavirus or just a common cold?
Andes virus/HPS typically lacks the "wet" symptoms of a cold, such as a runny nose or a productive cough, during the early stages. The presence of severe muscle aches, high fever, and a history of being in rural South America are significant indicators that should prompt an immediate medical consultation.
What should I do if I find a dead rodent in an endemic area?
Do not touch the rodent with bare hands. Wear gloves and a mask. Spray the rodent and the surrounding area with a disinfectant (like a bleach solution). Once thoroughly soaked, use a shovel or gloves to place the rodent in a plastic bag, seal it, and dispose of it according to local health guidelines.
Is it safe to travel to the Patagonia region?
Yes, it is generally safe, provided you follow standard precautions. Most travelers are at very low risk. The danger is highest for those engaging in "off-the-beaten-path" activities, such as cleaning old cabins, sleeping in rustic shelters, or trekking through dense brush where rodents are active.
Practical Recommendation
If you live in or are traveling to endemic regions of Argentina or Chile, the most critical action is to remain vigilant regarding respiratory health following any potential rodent exposure. If you develop a high fever and muscle aches within six weeks of visiting rural areas, seek medical attention immediately and specifically inform the healthcare provider about your travel history. Early hospitalization and the preemptive monitoring of oxygen saturation can be the difference between a successful recovery and a fatal outcome. Avoid all contact with individuals known to have HPS unless you are a trained professional using full biocontainment protocols.
